Drug Trial Radar · NCT06523231
Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Apr 7, 2025
Primary completion
Aug 27, 2025
Study completion Jan 22, 2026
Sponsor
- Lead sponsor
- LimmaTech Biologics AGIndustry
- Sponsor type
- Industry
- Collaborators
- Kenya Medical Research Institute
- First posted
- Jul 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 8 months, up to 10 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this study, the second-generation tetravalent bioconjugate candidate vaccine Shigella4V2 will be tested to confirm data on its safety and immunogenicity in infants and to identify the best dose of Shigella4V2 in 9-month-old infants.
Conditions
- Shigellosis
Interventions
Shigella4V2Biological
Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.
MenACWYBiological
Control vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Solicited Local and Systemic Adverse Events (AEs)Time frame: During 7 days following each vaccination
- Safety - Unsolicited Adverse Events (AEs)Time frame: During 28 days following each vaccination
- Safety - Serious Adverse Events (SAEs)Time frame: Throughout the study, up to 9 months
- Immunology - change in serum immunoglobulin G (IgG)Time frame: From first vaccination until 1 month following the second vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
KEMRI - Center for Global Health Research
Kisumu, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.